Astegolimab met its primary endpoint in the Phase IIb ALIENTO trial with a 15.4% reduction in annualized exacerbation rate at 52 weeks, while the Phase III ARNASA study showed a 14.5% reduction and ...

Topline data were announced from two phase 3 trials evaluating astegolimab in patients with moderate to very severe COPD.

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...

Roche’s IgG2 monoclonal antibody (mAb) astegolimab has yielded mixed results in chronic obstructive pulmonary disease (COPD), ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase ...

Basel: Roche has announced topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) ...

Between baseline and week 16, patients in the astegolimab group experienced an adjusted mean percent change of –51.47% (95% CI, –68.75 to –34.19) in their Eczema Area and Severity Index ...

Swiss pharma giant Roche today reported mixed results from late-stage trials for its experimental drug astegolimab, which is ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...